Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effectiveness of the study drug pacritinib
in people with relapsed or refractory lymphoproliferative disorders.